Treating Fragile X syndrome with the diuretic bumetanide: A case report

Acta Paediatrica, International Journal of Paediatrics

Volumn 102, Issue 6, 2013, Pages

  Lemonnier, Eric ^a   Robin, Gaëlle ^b   Degrez, Céline ^b   Tyzio, Roman ^c   Grandgeorge, Marine ^a,b   Ben Ari, Yehezkel ^c,d  

^a UNIVERSITÉ DE BRETAGNE OCCIDENTALE   (France)

^b BREST UNIVERSITY HOSPITAL   (France)

^c Turing Center for Living Systems CENTURI Aix Marseille University   (France)

^d INSERM   (France)

Author keywords

Autism spectrum disorders; Bumetanide; Fragile X; GABA; Intracellular levels of chloride

Indexed keywords

BUMETANIDE;

ABC SCALE; ARTHRALGIA; ARTICLE; ASTHENIA; AUTISM; AUTISM DIAGNOSTIC OBSERVATION SCHEDULE; BLOOD CHEMISTRY; CARS SCALE; CASE REPORT; CHILD; CLINICAL TRIAL (TOPIC); DIARRHEA; DISEASE SEVERITY; DIURETIC THERAPY; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG USE; DSM-IV; ECHOENCEPHALOGRAPHY; ELECTROENCEPHALOGRAM; EVENING DOSAGE; FRAGILE X SYNDROME; GENETIC SCREENING; HERNIOPLASTY; HISTOPATHOLOGY; HUMAN; HYPOKALEMIA; INGUINAL HERNIA; INTELLIGENCE QUOTIENT; KARYOTYPING; MALE; MORNING DOSAGE; MYALGIA; NAUSEA; ORTHOSTATIC HYPOTENSION; PHYSICAL EXAMINATION; PHYSIOTHERAPY; PRIORITY JOURNAL; RATING SCALE; REGULATION DISORDERS EVALUATION GRID; RRB SCALE; SCHOOL CHILD; SPEECH REHABILITATION; TREATMENT OUTCOME; VERTIGO;

BUMETANIDE; CHILD; CHILD DEVELOPMENT DISORDERS, PERVASIVE; DIURETICS; FRAGILE X SYNDROME; HUMANS; HYPOKALEMIA; MALE;

EID: 84877302187     PISSN: 08035253     EISSN: 16512227     Source Type: Journal    
DOI: 10.1111/apa.12235     Document Type: Article

References (30)

1. Bassell GJ, Warren ST,. Fragile X syndrome: loss of local mRNA regulation alters synaptic development and function. Neuron 2008; 60: 201-14.
2. Koukoui SD, Chaudhuri A,. Neuroanatomical, molecular genetic, and behavioral correlates of fragile X syndrome. Brain Res Rev 2007; 53: 27-38.
3. Kielinen M, Rantala H, Timonen E, Linna SL, Moilanen I,. Associated medical disorders and disabilities in children with autistic disorder-A population-based study. Autism 2004; 8: 49-60.
4. Reddy KS,. Cytogenetic abnormalities and fragile-X syndrome in autism spectrum disorder. BMC Med Gen 2005; 6: 3.
5. Clifford S, Dissanayake C, Bui QM, Huggins R, Taylor AK, Loesch DZ,. Autism spectrum phenotype in males and females with fragile x full mutation and premutation. J Autism Dev Disord 2007; 37: 738-47.
6. Kaufmann WE, Cortell R, Kau CSM, Bukelis I, Tierney E, Gray RM, et al. Autism spectrum disorder in fragile X syndrome: communication, social interaction, and specific behaviors. Am J Med Gen 2004; 129: 225-34.
7. Garber KB, Visootsak J, Warren ST,. Fragile X syndrome. Eur J Hum Genet 2008; 16: 666-72.
8. Penagarikano O, Mulle JG, Warren ST,. The pathophysiology of fragile X syndrome. Ann Rev Genom Hum G 2007; 8: 109-29.
9. Upner JJ,. New research on Fragile X syndrome. NY: Nova Science Publishers, Inc., 2007.
10. Jacquemont S, Hagerman RJ, Hagerman PJ, Leehey MA,. Fragile-X syndrome and fragile X-associated tremor/ataxia syndrome: two faces of FMR1. Lancet Neurol 2007; 6: 45-55.
11. Hagerman R, Lauterborn J, Au J, Berry-Kravis E,. Fragile X syndrome and targeted treatment trials. Results Probl Cell Differ 2012; 54: 297-335.
12. Berry-Kravis E, Hessl D, Coffey S, Hervey C, Schneider A, Yuhas J, et al. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J Med Genet 2009; 46: 266-71.
13. Lemonnier E, Ben-Ari Y,. The diuretic bumetanide decreases autistic behaviour in five infants treated during 3 months with no side effects. Acta Paediatr 2010; 99: 1885-8.
14. Lemonnier E, Degrez C, Phelep M, Tyzio R, Josse F, Grandgeorge M, et al. A randomized controlled trial of bumetanide in the treatment of autism in children. Transl Psychiatry 2012; 11: e202.
15. Chao HT, Chen HM, Samaco RC, Xue MS, Chahrour M, Yoo J, et al. Dysfunction in GABA signalling mediates autism-like stereotypies and Rett syndrome phenotypes. Nature 2010; 468: 263-9.
16. Coghlan S, Horder J, Inkster B, Mendez MA, Murphy DG, Nutt DJ,. GABA system dysfunction in autism and related disorders: from synapse to symptoms. Neurosci Biobehav Rev 2012; 36: 2044-55.
17. Tabuchi K, Blundell J, Etherton MR, Hammer RE, Liu X, Powell CM, et al. A neuroligin-3 mutation implicated in autism increases inhibitory synaptic transmission in mice. Science 2007; 318: 71-6.
18. Pizzarelli R, Cherubini E,. Alterations of GABAergic signaling in autism spectrum disorders. Neural Plast 2011; 24: 1-12.
19. Nardou R, Yamamoto S, Chazal G, Bhar A, Ferrand N, Dulac O, et al. Neuronal chloride accumulation and excitatory GABA underlie aggravation of neonatal epileptiform activities by phenobarbital. Brain 2011; 134: 987-1002.
20. Dzhala VI, Kuchibhotla KV, Glykys JC, Kahle KT, Swiercz WB, Feng G, et al. Progressive NKCC1-dependent neuronal chloride accumulation during neonatal seizures. J Neurosci 2010; 30: 11745-61.
21. Boulenguez P, Liabeuf S, Bos R, Bras H, Jean-Xavier C, Brocard C, et al. Down-regulation of the potassium-chloride cotransporter KCC2 contributes to spasticity after spinal cord injury. Nat Med 2010; 16: 302-7.
22. Marrosu F, Marrosu G, Rachel MG, Biggio G,. Paradoxical reactions elicited by diazepam in children with classical autism. Funct Neurol 1987; 2: 355-61.
23. Lord C, Rutter M, Le Couteur A,. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994; 24: 659-85.
24. Lord C, Rutter M, Goode S, Heemsbergen J, Jordan H, Mawhood L, et al. Autism diagnostic observation schedule: a standardized observation of communicative and social-behavior. J Autism Dev Disord 1989; 19: 185-212.
25. DiLalla DL, Rogers SJ,. Domains of the childhood autism rating scale: relevance for diagnosis and treatment. J Autism Dev Disord 1994; 24: 115-28.
26. Rogers SJ, Ozonoff S, Maslin-Cole C,. Developmental aspects of attachment behavior in young children with pervasive developmental disorders. J Am Acad Child Adolesc Psychiatry 1993; 32: 1274-82.
27. Aman MG, Singh NN, Stewart AW, Field CJ,. Psychometric characteristics of the aberrant behavior checklist. Am J Ment Defic 1985; 89: 492-502.
28. Adrien JL, Rossignol-Deletang N, Martineau J, Couturier G, Barthelemy C,. Regulation of cognitive activity and early communication development in young autistic, mentally retarded, and young normal children. Dev Psychobiol 2001; 39: 124-36.
29. Bourreau Y, Roux S, Gomot M, Barthelemy C,. Repetitive and restricted behaviours (RRB) in autism: clinical evaluation. Encephale 2009; 35: 340-6.
30. Heulens I, D'Hulst C, Braat S, Rooms L, Kooy RF,. Involvement and Therapeutic Potential of the GABAergic System in the Fragile X Syndrome. Sci World J 2010; 10: 2198-206.